| Identification | Back Directory | [Name]
AUY954 | [CAS]
820240-77-5 | [Synonyms]
AUY954
AUY-954 free base
AUY 954 free base,AUY954 free base
β-Alanine, N-[[2-[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]benzo[b]thien-5-yl]methyl]- | [Molecular Formula]
C25H20F3NO2S | [MOL File]
820240-77-5.mol | [Molecular Weight]
455.5 |
| Chemical Properties | Back Directory | [Boiling point ]
646.3±55.0 °C(Predicted) | [density ]
1.314±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml | [form ]
A crystalline solid | [pka]
3.62±0.12(Predicted) |
| Hazard Information | Back Directory | [Description]
AUY954 is an orally bioavailable and selective agonist of the sphingosine-1-phosphate receptor 1 (S1P1; EC50 = 1.2 nM for stimulating GTPγS binding to S1P1 in CHO cells). It is highly selective for the S1P1 receptor with EC50 values of >10,000, 1,210, >1,000, and 340 nM for S1P2, S1P3, S1P4, and S1P5 receptors, respectively. AUY954 reduces circulating lymphocytes and prevents rejection of rat heart allografts. In a rat model of experimental autoimmune neuritis, chronic treatment with AUY954 (10 mg/kg), starting on the day of immunization, almost completely prevents peripheral paralysis. In the same model, it also decreases T cell, B cell, and macrophage infiltration and perivascular demyelination in sciatic nerves. |
|
|